Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis

Running, not recruitingNot a drug-phase studyRelapsing MSNCT04009005

What it found

Still running

No result yet.

What was tested

Treatment tested

  • Therapeutic diet and lifestyle

What it measured

Main measures

  • MS 54 Quality of Life scale physical health score

    change from baseline to 12 months

    Quality of life (reported by participants)
  • MS 54 Quality of Life scale mental health score

    change from baseline to 12 months

    Quality of life (reported by participants)

Other measures (10)

  • Fatigue Severity Score

    Baseline to 12

    Fatigue
  • Modified Fatigue Impact Scale

    Baseline to 12

    Fatigue
  • Perceived Deficits Questionnaire

    Baseline to 12

  • Anxiety Score -Hospital Anxiety and Depression Survey

    change from baseline to 12 months

    Mood and sleep
  • Depression score -Hospital Anxiety and Depression Survey

    change from baseline to 12 months

    Mood and sleep
  • MS Clinical symptoms over time

    baseline to 6 months

  • MS Clinical symptoms over time

    baseline to 12 months

  • MS Clinical symptoms over time

    baseline to 18 months

  • MS Clinical symptoms over time

    baseline to 24 months

  • Dietary intake

    baseline to 12 months

Who could take part

Relapsing MS · 18 to 55

Show the full criteria

Inclusion criteria

* 1) A diagnosis of clinically isolated syndrome (CIS) or relapsing-remitting multiple sclerosis (RRMS) or CIS according to the 2010 McDonald's criteria, confirmed by the treating neurologist within 12 months of completing the first study visit. and having received a recommendation to begin disease modifying treatment (DMT)2) Must consent to sharing the clinical notes from their primary care and neurology providers during the study period.3) Must reside within the lower 48 states within the United States.4) Agreement by the treating neurologist that the patient may enroll in the study.

Exclusion criteria

1) Moderate or severe mental impairment as measured by the Short Portable Mental Health Questionnaire. 2) Taking insulin or Coumadin® medication. 3) History of oxalate kidney stones, schizophrenia, or active diagnosis of eating disorder. 4) Greater than 12 months since initial diagnosis of RRMS or CIS and first study visit.

As registered. Criteria can change, so ask the trial team or your neurologist.

About this trial

In the sponsor's words

A key question in efforts to reduce symptoms and improve quality of life for multiple sclerosis (MS) patients is whether a therapeutic lifestyle (diet, stress reduction and exercise) is inferior to disease-modifying drug treatments in terms of reducing multiple sclerosis related symptoms, improving function and quality of life. This study will prospectively assess the changes in quality of life and clinical outcomes in two cohorts of patients who are recently diagnosed with clinically isolated syndrome (CIS) or relapsing-remitting multiple sclerosis (RRMS) to begin answering that question. The goal of this project is to compare a diet and therapeutic lifestyle only treatment usual care in the setting of newly diagnosed individuals with RRMS or CIS, which is the precursor to the development of MS. Due to the COVID 19 Pandemic, the study was redesigned from an in-person study to a virtual visit only study prior to enrolling study subjects.

Papers

Loading reviews and guidelines…

History

    1. Started

      May 2020

    2. Main results due

      Aug 2022

    3. Finished

      Sept 2027

    Assembled by software from public sources.